Dr Reddy’s Laboratories has moved higher by over 2% at Rs 1,880 after the company said it has launched Finasteride tablets (1 mg), a bioequivalent generic version of Propecia in the US market on Wednesday.
“The company has launched Finasteride tablets (1 mg), a bioequivalent generic version of Propecia (Finasteride) tablets in the US market on January 2, 2013,” Dr Reddy’s Laboratories said in a statement.
Dr Reddy’s ANDA for Finasteride tablets has been awarded a 180-day period for marketing exclusively in the US on January 2, 2013, it added.
According to IMS Health, the Propecia tablets brand has US sales of approximately $136 million MAT for the most recent twelve months ending in October 2012.
The stock opened at Rs 1,849 and hit a high of Rs 1,884 after the announcement on the NSE. A combined 183,746 shares have changed hands on the counter so far on both the exchanges.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app